Search Results

Sensei Biotherapeutics, Inc. today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium.

Beacon Therapeutics Holdings Limited, a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501.

Model N announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners, a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.

Mirum Pharmaceuticals, Inc. announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis.

Kineta, Inc. (Nasdaq: KA) announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024.

SINGAPORE and HANOVER, March 13, 2024 – Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).